A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium
EZN-3042（一种新型 survivin 信使核糖核酸 (mRNA) 拮抗剂）联合化疗治疗复发性急性淋巴细胞白血病 (ALL) 儿童的 I 期研究：儿童白血病和淋巴瘤治疗进展 (TACL) 联盟的报告
期刊:Journal of Pediatric Hematology Oncology
影响因子:
doi:10.1097/MPH.0b013e3182a8f58f
Elizabeth A Raetz, Debra Morrison, Eleny Romanos-Sirakis, Paul Gaynon, Richard Sposto, Deepa Bhojwani, Bruce C Bostrom, Patrick Brown, Elena Eckroth, Jeannette Cassar, Jemily Malvar, Aby Buchbinder, William L Carroll
